The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 45 | Mesenteric peritonectomy and cytoreductive surgery in peritoneal surface malignancies
Francesca Nava, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, presents outcomes from a cohort analysis of mesenteric peritonectomy in peritoneal surface malignancies. Despite the added surgical burden when adding peritonectomy to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), the technique introduces no additional morbidity. The findings address a gap in the literature, as no prior outcome reports exist for this combined approach in clinical practice. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...